New Data For Jakafi® (ruxolitinib) To Be Presented At The 2012 American Society Of Hematology Annual Meeting

Incyte Corporation (Nasdaq: INCY) announced today that several analyses from clinical studies of Jakafi® (ruxolitinib) will be presented at the 2012 American Society of Hematology (ASH) Annual Meeting from Dec. 8 to 11 at the Georgia World Congress Center in Atlanta. Jakafi, an oral Janus kinase (JAK) inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF).

The following abstracts, which are related to the use of Jakafi in patients with MF, will be oral presentations (dates, times and locations of the presentations are included):

• Abstract #176 – Oral Presentation – Sunday, Dec. 9, 4:45 p.m. EST
  • Talpaz, M, et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50–100 x 10 ⁹ /L): A comparison to patients with normal or high starting platelet counts.
  • Location: B213-B214, Level 2, Building B
• Abstract #177 – Oral Presentation – Sunday, Dec. 9, 5 p.m. EST
  • Harrison, C, et al. Expand: a Phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 × 10 ⁹ /L and 99 × 10 ⁹ /L.
  • Location: B213-B214, Level 2, Building B
• Abstract #800 – Oral Presentation – Monday, Dec. 10, 6:30 p.m. EST
  • Verstovsek, S, et al. Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: Durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I.
  • Location: B213-B214, Level 2, Building B
• Abstract #801 – Oral Presentation – Monday, Dec. 10, 6:45 p.m. EST
  • Cervantes, F, et al. Long-term safety, efficacy, and survival findings from COMFORT-II, a Phase III study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis.
  • Location: B213-B214, Level 2, Building B
• Abstract #802 – Oral Presentation – Monday, Dec. 10, 7 p.m. EST
  • Vannucchi, A, et al. Reductions in JAK2 V617F allele burden with ruxolitinib treatment in COMFORT-II, a Phase III study comparing the safety and efficacy of ruxolitinib with best available therapy.
  • Location: B213-B214, Level 2, Building B

The following abstracts, which are related to the use of Jakafi in patients with MF, will be presented during poster sessions:

• Abstract #1727 - Poster Presentation – Saturday, Dec. 8, 5:30-7:30 p.m. EST
  • Mesa, R, et al. Clinical benefits of ruxolitinib therapy in myelofibrosis patients with varying degrees of splenomegaly and symptoms.
  • Location: Hall B1-B2, Level 1, Building B
• Abstract #1733 – Poster Presentation – Saturday, Dec. 8, 5:30-7:30 p.m. EST
  • Mesa, R, et al. Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I.
  • Location: Hall B1-B2, Level 1, Building B
• Abstract #2838 – Poster Presentation – Sunday, Dec. 9, 6-8 p.m. EST
  • McMullin, M, et al. The use of erythropoietic-stimulating agents with ruxolitinib in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
  • Location: Hall B1-B2, Level 1, Building B
• Abstract #2847 – Poster Presentation – Sunday, Dec. 9, 6-8 p.m. EST
  • Verstovsek, S, et al. Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: A retrospective analysis of data from ruxolitinib clinical trials.
  • Location: Hall B1-B2, Level 1, Building B
• Abstract #4255 – Poster Presentation – Monday, Dec. 10, 6-8 p.m. EST
  • Ouagari, K, et al. Cost-effectiveness of ruxolitinib versus best-available therapy for medical treatment of myelofibrosis: Canadian societal perspective.
  • Location: Hall B1-B2, Level 1, Building B

Other data related to Jakafi to be presented at ASH include:

• Abstract #2844 – Poster Presentation – Sunday, Dec. 9, 6-8 p.m. EST
  • Barosi, G, et al. An individual patient supply program for ruxolitinib for the treatment of patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
  • Location: Hall B1-B2, Level 1, Building B
• Abstract #804 – Oral Presentation – Monday, Dec. 10, 7:30 p.m. EST
  • Verstovsek, S, et al. Long-term efficacy and safety results from a Phase II study of ruxolitinib in patients with polycythemia vera.
  • Location: B213-B214, Level 2, Building B

About the Webcast

Incyte will host an investor meeting to discuss the new Jakafi data being presented at ASH. The presentation will be webcast live at 8:45 p.m. EST on December 10, 2012, and can be accessed at www.incyte.com under Investor Relations, Events and Webcasts. A replay of the event will be available for 60 days.

About Jakafi

Jakafi is a prescription medicine used to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.

1 2 3 Next › Last »